A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs M 6620 (Primary)
- Indications Leiomyosarcoma; Osteosarcoma; Solid tumours
- Focus Therapeutic Use
- 11 Jan 2019 Status changed from not yet recruiting to recruiting.
- 11 Jan 2019 Last checked against ClinicalTrials.gov record.
- 01 Nov 2018 New trial record